Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

CD37 is a lineage-specific B-cell antigen that to date has been neglected as an attractive therapeutic target. To exploit this, novel CD37-specific small modular immunopharmaceuticals (CD37-SMIP) that include variable regions linked to modified human IgG(1) hinge, CH(2), and CH(3) domains were desig...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhao, Xiaobin, Lapalombella, Rosa, Joshi, Trupti, Cheney, Carolyn, Gowda, Aruna, Hayden-Ledbetter, Martha S., Baum, Peter R., Lin, Thomas S., Jarjoura, David, Lehman, Amy, Kussewitt, Donna, Lee, Robert J., Caligiuri, Michael A., Tridandapani, Susheela, Muthusamy, Natarajan, Byrd, John C.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2007
Materias:
Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1988922/
https://ncbi.nlm.nih.gov/pubmed/17440052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-12-062927
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares